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Because of increasing opioid use among pregnant women,1
the incidence of neonatal abstinence syndrome (NAS) in the
United States rose from 3.4 to 5.8 per 1,000 hospital births
between 2009 and 2012,2 and the condition has been labeled
a national epidemic. Because a signiﬁcant proportion of cases
are treated in intensive care nurseries,3 the cost of hospitali-
zation for full treatment and weaning using the conventional
approach is high. Between 2000 and 2012, U.S. mean hospital
charges for a newborn with NAS increased from $39,400 to
$66,700, with Medicaid as the primary payer.2,4
In a 2000–2007 national study of opioid use during
pregnancy among Medicaid-enrolled women, Desai et al
reported that 21% of women ﬁlled an opioid prescription
during pregnancy.5 In a 2005–2011 study utilizing a national
sample of privately insured women, Bateman et al reported
the prevalence of any opioid use anytime during pregnancy to
be 14.4%.6 Little information exists about opioid use among
pregnant women entering substance use treatment pro-
grams7; however, for 19% of pregnant and nonpregnant
women, opioids are the primary substance misused.8 Metha-
done has been widely accepted for use in pregnant women
with opioid use disorders since the 1970s.9,10 Since 1998,
methadone has been the recommended standard of care for
this population.11 Medical maintenance treatment with
methadone has the same beneﬁts for pregnant patients as
for patients in general. Comprehensive maintenance treat-
ment including prenatal care signiﬁcantly reduces neonate
morbidity and mortality12; however, it also raises the risk for
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Abstract Objective To describemedical, safety, and health care utilization outcomes associated
with an early treatment model for neonatal opioid withdrawal.
Study Design This is a retrospective review of 117 opioid-exposed infants born in a
large regional hospital and treated in the level I nursery with methadone initiated within
48 hours of birth.
Results For this cohort, mean length of stay was 8.3 days. Hospital safety events were
infrequent; there were nomedication errors or deaths. Within 30 days of discharge, 14%
of infants visited the emergency department; 7% were readmitted. Per birth, mean
hospital charges were $10,946.96; mean costs were $5,908.93.
Conclusion This study is the ﬁrst to describe an early treatment model in a low-acuity
nursery to prevent severe neonatal opioid withdrawal. The described model may be
safe, effective, low-cost, and feasible for replication.
received
July 2, 2016
accepted after revision
October 25, 2016
Copyright © by Thieme Medical
Publishers, Inc., 333 Seventh Avenue,
New York, NY 10001, USA.
Tel: +1(212) 584-4662.
DOI http://dx.doi.org/
10.1055/s-0036-1596054.
ISSN 0735-1631.
Original Article
D
ow
nl
oa
de
d 
by
: G
re
en
vil
le
 H
os
pi
ta
l S
ys
te
m
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
neonatal opioid withdrawal. According to the Tennessee
Department of Health’s 2015 NAS surveillance report, more
than half of cases statewide were attributable to supervised
opioid replacement therapy.13 These data are consistent with
earlier sources that estimated NAS prevalence at 48 to 95%
in neonates born to women in opioid maintenance treat-
ment.14,15 Therefore, care models focused on infants born to
mothers in recovery may be able to address a signiﬁcant
proportion of NAS cases.
The conventional approach to managing NAS holds great
challenges. No formal national guidelines for managing NAS
yet exist,16–18 but standard practice is to delay pharmaco-
therapy until a newborn displays sufﬁcient objective signs
and symptoms to justify treatment.16,19–21 This practice is
based on several inﬂuences: NAS signs vary considerably and
depend on several factors;22–24 some infants may be ade-
quately managed with nonpharmacologic care;21 pharmaco-
therapy is typically administered only in high-acuity
settings;3 withdrawal is believed to be a self-limited process
and has undeﬁned long-term morbidities;21 and studies
suggest that prolonged fetal opioid exposure may cause
harm.25–31 In past decades, developing recommendations
for pain management in neonates was similarly challenging.
Pain symptoms in neonates are likewise nonspeciﬁc and vary
considerably. There is noway to deﬁne the degree of pain that
speciﬁc minor or major procedures will cause for a speciﬁc
infant. However, research now supports the concept that pain
experiences in neonates have the potential to causeharm, and
the prevention and effective management of pain should be a
goal of those caring for at-risk neonates.32,33 Because neuro-
logic pathways for pain and withdrawal are similar, methods
for managing NAS should achieve a similar goal.
New models for treating conﬁrmed NAS have been
described that support expanding beyond conventional
approaches. Patrick et al reported that methadone as initial
treatment was associated with reduced hospital stay and
duration of opioid therapy.17 Backes et al demonstrated
that a combined inpatient and outpatient treatment model
reduces hospital stay and costs.34 Johnston et al recom-
mended methadone for pharmacologic treatment and
outlined a standardized approach for inpatient care and
outpatient weaning.35 A model of prevention has not yet
been explored. Hudak et al described the concept that “each
clinical unit can establish a threshold level of cumulative
[iatrogenic] exposure to opioids… above which drug depen-
dency can be expected to occur with a likelihood that justiﬁes
anticipatory initiation of a weaning protocol.”21 In the same
way, continuous fetal opioid exposure due to placental trans-
fer of maternal long-acting opioid therapy in late gestation
may also justify initiation of a weaning protocol immediately
after birth. According to Hall’s multicenter cohort study of
outcomes related to NAS, the mean onset of symptoms was
46.1 hours of age,3 which is consistent with other reports in
the literature.19–21,36–38 At its peak, withdrawal is difﬁcult to
manage. By the time symptoms are controlled with pharma-
cotherapy, signiﬁcant suffering and physical effects have
often already occurred. These are well-documented to
include excessiveweight loss, feeding problems, self-inﬂicted
excoriations, perianal maceration, vomiting, diarrhea, dehy-
dration, and disruption of bonding and breast-feed-
ing.19,21,39,40 Supportive therapies such as high-calorie
feedings, intravenous ﬂuids, treatments for perianal skin
breakdown, therapies for hypertonicity, and disorganized
feeding patternsmaybe needed to reverse the physical effects
that occurred while waiting for enough objective evidence to
rationalize pharmacotherapy. If withdrawal leads to newborn
fever, additional blood work, procedures, and intravenous
antibiotic treatment may be added. Therefore, delayed treat-
ment may contribute to longer hospitalization, and medical
complications of withdrawal must be addressed. The objec-
tive of this study was to describe medical, safety, and health
care utilization outcomes associated with an early treatment
model for neonatal opioid withdrawal.
Patients and Methods
This study is a descriptive analysis of newborns at high risk for
opioid withdrawal who were treated with early methadone
(within 48 hours) in a level I newborn care setting during 2006
to 2014. The study hospital is a large, regional perinatal referral
center containing 710 beds with an average annual volume of
5,221 births from 2006 to 2014. This hospital is part of a public,
not-for-proﬁt academic health care delivery system. Approval
from institutional review board was obtained prior to the
study. Data collection was performed through data extraction
from electronic medical records and direct chart review. All
data were abstracted by a trained research assistant. The
standard deﬁnition for an NAS birth was established prior to
abstraction as ICD-9 code(s) 779.5 and/or 760.72. The exclu-
sion criteria were admitted to neonatal intensive care imme-
diately after birth, methadone not administered within 48
hours, and transfer to intensive care for complications or illness
prior to completion of the treatment model.
Analysis of outcomes related to health, safety, health
services utilization, and cost was conducted. Descriptive
statistics (frequency, percent, mean, median, range, and
standard deviation [SD]) were generated using Stata 14
(StataCorp, College Station, Texas). Results are presented as
mean (SD) if not otherwise indicated. Primary outcome
measures included hospital length of stay; need for adjunc-
tive medication; medical complications requiring transfer to
a higher level of care; adverse medication and safety events;
readmission rates; and total hospital charges, cost, and reve-
nue per case.
Early Treatment Model Description
The early treatment model, developed in 2003, is based on the
theory that neonates chronically exposed to long-acting
opioids in late gestation are born in steady state. Research
has demonstrated signiﬁcant transfer of opioids across the
placenta.41When startedwithin 24 hours of birth, methadone
may be considered a continuation of therapy and prevent
severe opioid withdrawal and its complications. The model
was developed by a multidisciplinary team, including repre-
sentatives from pediatric and developmental medical staff,
pediatric pharmacy, nursing administration, nursing staff,
American Journal of Perinatology
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social work, physical and occupational therapies, and child
advocacy. The literature supports that 55 to 94% of neonates
with chronic fetal exposure to long-acting opioids will experi-
ence clinically signiﬁcant withdrawal.21 For the small percent-
age of newbornswhomay receive unnecessary pharmacologic
therapy under the early treatment model, the team decided to
ensure that infants are formally screened for vital sign changes
and symptoms of oversedation during hospitalization.
The original model evolved over the course of a decade.
Early changes included the development of preprinted order
sets, changing a mandated 10-day stay for all at-risk new-
borns to a length of stay driven bymedical need, an option for
mothers to room-in for the entire newborn stay, and selection
of methadone as the preferred pharmacotherapy to prevent
severe opioid withdrawal. Additional changes included
assignment of all newborns discharged on medication to
one pediatric medical home for the duration of weaning,
dispensing methadone in preﬁlled oral syringes, changing a
requirement for caregivers to complete infant cardiopulmo-
nary resuscitation (CPR) training prior to discharge to pro-
viding caregivers with formal education about safe sleeping
environments, and recommending community-based infant
CPR classes. Structure was added to the outpatient weaning
process, with a target wean of 30 days and 15% dose reduc-
tions on prescribed days.
Currently, infants admitted to themother/baby unit whose
mothers are taking chronic long-acting opioids are offered
early treatment, breast-feeding support (unless contraindi-
cated), and extended stay for the hospitalization. Potential
risks and beneﬁts of early treatment are reviewed with
parents; they are allowed to decline but are informed of
symptom thresholds that will require pharmacotherapy dur-
ing thebirth hospitalization. All neonates deemed to be at risk
for withdrawal are managed by a newborn hospitalist and
receive low-stimulation supportive care. Infants exposed to
maternal methadone doses of 60 mg or higher are started on
0.1 mg/kg/dose every 6 hours; those exposed to less metha-
done or buprenorphine are started on 0.05 mg/kg/dose every
6 hours. A pediatric pharmacist is involved with all cases for
dosing recommendations and development of the weaning
calendar. Urine and meconium drug screening and prescrip-
tion monitoring database queries are routinely performed. To
address the concern that a small percentage of neonates
administered early methadone may be overtreated, continu-
ousmonitoring for apnea and bradycardia is performed in the
mother’s room to screen for low heart and respiratory rate,
and modiﬁed Finnegan scoring and evaluation for overseda-
tion is performed every 4 hours by trained mother/baby
nursing staff. A social work evaluation is completed for all
families. Any feeding supplementation, whether by maternal
choice or physician order, is initiated with expressed breast
milk or standard 0.67 kcal/mL formula.
Methadone dose adjustments are made for each patient
based on all available evidence, including physician exami-
nation, nursing and parent reports, input from therapists,
abstinence scores, weight loss, feeding and elimination
patterns, and pediatric pharmacist recommendations. Scores
alone do not drive dosing decisions. For suspected over-
sedation, continuous pulse oximetry is initiated, methadone
is held until symptoms resolve, and then methadone is
restarted at a lower dose or increased interval. For poor
symptom control, methadone dosing is increased by 0.05
mg/kg approximately every 36 to 48 hours, to a maximum of
0.2 mg/kg/dose. Once abstinence scores are consistently eight
or lower for 36 to48 hours, themethadone interval is changed
to 8-hour dosing, maintaining the same total daily dose. After
another 36 to 48 hours with stable scores, the methadone
interval is changed to 12-hour dosing, maintaining the same
total daily dose. After a ﬁnal 36 to 48 hourswith stable exams,
scores, vital signs, and weight, the infant is discharged to an
appropriate caregiver for outpatient weaning. All infants are
discharged on methadone. A weaning calendar is developed
by a pediatric pharmacist, and methadone is dispensed in
preﬁlled oral syringes from thehospital outpatient pharmacy,
which has an average out-of-pocket cost of $13. Caregivers are
required to ﬁll the prescription prior to discharge, and unit
staff personnel reconcile that all needed syringes have been
dispensed and that caregivers understand how to administer
medication per the calendar. Apnea/bradycardia monitoring
and abstinence scoring are discontinued at discharge.
Dosage reductions of approximately 15% (of the discharge
dose) occur every Sunday and Wednesday. Ofﬁce visits occur
at the outpatient pediatric medical home weekly during
weaning to evaluate the effect of medication reduction.
Outpatient physicians assess for signs or symptoms of poor
NAS control and slow down the weaning process if necessary.
One or two home nursing visits are provided through the
regional health department ofﬁce. Families are educated
about signs of uncontrolled withdrawal that should prompt
additional visits; they are not asked to do formal scoring. All
newborns are referred for formal developmental assessment
at 3 or 4 months as well as to phone-based parenting support
and developmental screening services (Help Me Grow,
Greenville, SC) that are available to up to age 8.
Results
From 2006 to 2014, early methadone treatment was provided
for 143 infants within 48 hours of birth. After early methadone
administration, 26 infantswere transferred toneonatal intensive
care for medical illness or complications including fever
(n ¼ 10; 38%), hypoglycemia (n ¼ 7; 27%), respiratory distress
(n ¼ 6; 23%), supraventricular tachycardia (n ¼ 1; 4%), bilious
emesis (n ¼ 1; 4%), and feedingdifﬁculty (n ¼ 1; 4%). In the level
I nursery, 117 newborns completed the early treatment model.
Cohort selection criteria are detailed in►Fig. 1.►Tables 1 and2
outline the demographic and clinical characteristics of mothers
and their newborns in the studied cohort. Data tables for
maternal characteristics reﬂect each pregnancy or birth
separately.
Mean gestational age for newborns was 39 (SD: 1.6) weeks;
mean birthweight was 2,940 (SD: 465) g. Among mothers,
mean age was 28 (SD: 5.2) years, and 97% of mothers received
prenatal care, with a mean of 8.3 visits per pregnancy. Four
planned adoptions occurred. More than half of mothers
reported chronic mental health issues (►Table 2). The
American Journal of Perinatology
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reported categories are notmutuallyexclusive; for example, 29
mothers experienced both depression and anxiety, and
11 mothers experienced bipolar disorder and anxiety.
Mothers taking buprenorphine reported an average daily
dose of 14 (SD: 7) mg, and mothers taking methadone
reported an average daily dose of 96 (SD: 50) mg. Mothers
used medically assisted treatment for a variety of reasons:
addiction to illegal substances (25%), addiction to nonpre-
scribed opioids (46%), and dependence on/addiction to pre-
scription opioids for acute (20%) or chronic pain (19%).
Maternal use of other drugs was measured through
self-report as well as through infant urine and meconium
drug screens. Illicit drug use during the third trimester
triggered child protective services involvement but was
not an exclusion criterion for the early treatment model.
Nine (8%) mothers admitted illicit drug use after the ﬁrst
trimester. Newborn urine drug screens were conﬁrmed
positive for amphetamines in one infant and cocaine metab-
olites in two infants at delivery. Meconium drug screens
were conﬁrmed positive for amphetamines in one infant,
methamphetamines in one infant, and cocaine metabolites
in three infants.
►Table 3 summarizes medical and safety outcomes for
newborns treated with the model.
Forty-two percent in the cohort were fed breast milk; only
14 newborns required high-calorie supplementation. None
experienced dehydration or a need for intravenous ﬂuids.
Adverse hospital events were infrequent; there were no
medication errors and no deaths.
Seventy-ﬁve percent of patients met the targeted 30-day
outpatient wean after its implementation during 2012. Seven
patients visited the emergency department (ED) within
30 days of discharge and were not readmitted to the hospital.
Two presented with symptoms possibly NAS-related: one
medication issue and one diarrhea. Five of the discharged
patients presented with symptoms not related to NAS; they
were oral candidiasis, oral and diaper candidiasis, motor
vehicle accident, minor head injury, and Listeria bacteremia
(diagnosed after ED release). Nine patients were readmitted
to the hospital within 30 days of discharge; six were for
possible NAS-related issues, which included an event related
to gastroesophageal reﬂux, feeding problems, failure to
thrive, fever with NAS symptoms, and NAS symptoms alone.
Three were readmitted for conditions not related to NAS:
Live birth between January 2006 and June 
2014 with ICD-9 code 760.72 or 779.5:  
472 patients 
Admitted to neonatal intensive care 
immediately after delivery for 
gestational age < 35 weeks and/or 
ill-appearing at birth:   
93 patients 
Admitted to Level 1 newborn care immediately
after delivery: 379 patients 
Methadone never administered to 
newborn: 201 patients 
Methadone was administered to newborn: 
178 patients 
Methadone initiated after 48 hours of 
birth: 35 patients 
Methadone initiated within 48 hours of birth: 
143 patients 
Transferred to neonatal intensive care 
for medical illness or complication: 
26 patients
Completed palliative treatment model:  
117 patients 
Fig. 1 Cohort selection criteria. Retrospective chart review began with 472 newborn charts coded for withdrawal. Charts were excluded if the
newborn was admitted to intensive care immediately after birth, not administered methadone before 48 hours of age, or required transfer to
intensive care prior to discharge. In the level I newborn care setting, 117 patients completed the full early treatment model.
American Journal of Perinatology
Early Treatment for NAS Hudson et al.
D
ow
nl
oa
de
d 
by
: G
re
en
vil
le
 H
os
pi
ta
l S
ys
te
m
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
hypothermia, pertussis, and respiratory syncytial virus with
urinary tract infection.
All hospital charge, cost, and revenue data were adjusted
for inﬂation in 2014 USD. Per birth, mean total hospital
charges were $10,946.96; mean total hospital costs were
$5,908.63; and mean total revenue was $5,260.82. Mean
length of stay per case was 8.3 days. Reported ﬁgures do
not include any outpatient fees, ED charges, or physician fees
incurred after discharge.
Discussion
Signs and symptoms of newborn opioidwithdrawal have been
well described in the literature and are consistent with phases
of methadonewithdrawal reported in adults.19,21,39–41 After 1
to 3 days of abstinence, subjective symptoms of withdrawal
include fatigue, nausea, craving, irritability, depression,muscle
aches, and wakefulness. After 3 to 5 days of abstinence, severe
symptoms and objective signs manifest, such as involuntary
muscle spasms, arthralgias, muscle and bone pain, vomiting,
diarrhea, insomnia, fever, sneezing, yawning, and agitation.
In recent decades, increased attention has been given to
preventing pain in neonates. According to the American
Academy of Pediatrics (AAP), “The prevention of pain is
important not only because it is an ethical expectation but
also because repeated painful exposures can have deleterious
consequences,” including long-term disabilities.32 In addition,
the AAP reports that “early and effective pain treatment is
associatedwith a lower total dose ofmedication” and fears that
analgesics (especially opioids) may lead to hypotension or
respiratory depression has never been conﬁrmed in random-
ized controlled trials.32 According to Anand regarding the
management of mild to moderate pain in neonates, “The use
of environmental therapies (swaddling, sucrose, paciﬁers) and
decreased stimuli have limited therapeutic efﬁcacy.”33 No
reported treatment models for NAS have focused on the
prevention of suffering associated with the experience. In
contrast, experts to date have emphasized that newborn
withdrawal is “a self-limited process” and have de-emphasized
the importance of treating suffering until clearlymeasurable.32
The concept of weaning pediatric patients with opioid
dependence is not new. For those requiring prolonged life
support and opioid therapy, standard practice is to wean
opioids slowly over days to weeks to avoid the experience of
withdrawal and symptoms that may confuse a complex
medical course. Until now, this concept applied to fetal opioid
dependence has never been studied.
While NAS treatment commonly occurs in the intensive
care setting,3 there has been increased interest in lower-acuity
Table 2 Maternal demographic and clinical characteristics
(n ¼ 117)
Frequency (n) Percent (%)
Race
White 108 96
Black or African American 3 3
Two or more races 2 2
Marital status
Married 41 38
Never married 55 47
Divorced or widowed 16 14
Primigravida 21 18
Smoking during pregnancy 87 74
SSRI use during pregnancy 8 7
Benzodiazepine use
during pregnancy
37 32
Opioid used during pregnancy
Methadone 96 82
Buprenorphine 21 18
Mental health diagnosis (not mutually exclusive)
Depression 49 42
Anxiety disorder 43 37
Bipolar disorder 15 13
Postpartum depression 7 6
Posttraumatic
stress disorder
1 1
Abbreviation: SSRI, selective serotonin reuptake inhibitor.
A cohort of 108 mothers gave birth to 117 studied infants. One mother
had twins, and eight mothers had two infants at different times during
the study period. White mothers were 96%, 71% completed high school,
and 38% were married.
Table 1 Newborn demographic and clinical characteristics
(n ¼ 117)
Frequency (n) Percent (%)
Sex
Male 59 50
Female 58 50
Race
White 105 90
Black or African American 3 3
Hispanic, Latino,
or Spanish origin
1 1
Native Hawaiian or
other Paciﬁc Islander
2 2
Two or more races 6 5
Gestational age (wk)
35–36 12 10
37 23 20
38–42 80 70
Apgar score at 5 min  8 115 98
Small for gestational age 20 17
Insured by SC Medicaid 111 95
American Journal of Perinatology
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and community-based intervention strategies.17,34,35,42–44
The 8.3-day mean hospital stay for our sample was less than
half of that reported nationally for all NAS infants (mean: 16.9
days)2 and was approximately one-third the hospital stay for
pharmacologically treated NAS infants (mean: 23 days).2
Despite the signiﬁcant reduction in stay, adverse safety and
medical events for our studied cohort were low. Lee et al
reported similar low rates of complication for a combined
inpatient/outpatient model.42
In the studied cohort, early treatment for newborns with
signiﬁcant opioid exposure during late gestation promoted
early control of NAS symptoms without excessive risk of
oversedation. Appropriatemonitoring was effectively accom-
plished in a low-acuity setting; there were no reports of
oversedation after discharge.
Patients displayed peak NAS symptoms consistent with
the timing reported in other studies.3,19–21,36–38 The re-
searchers hypothesize that early treatment kept newborns
from entering severe opioid withdrawal, when most gastro-
intestinal symptoms manifest. The average infant did not
experience signiﬁcant feeding problems, excessive weight
loss, diarrhea, dehydration, or severe perianal maceration,
Table 3 Newborn outcomes (n ¼ 117)
Medical outcomes Median (range) Mean (SD)
Length of stay (d) 8 (4–18) 8.3 (2.7)
Peak weight loss (%) 7 (1–14) 7 (2.5)
Day of peak weight loss 4 (1–8) 3.7 (1.5)
Peak modiﬁed Finnegan score 10 (3–21) 10.4 (3.6)
Day of peak score 2 (0–7) 2.6 (1.7)
Methadone discharge dose (mg/kg/d) 0.4 (0.1–1.4) 0.5 (0.3)
Duration of outpatient methadone weana (d) 46 (10–96) 44.6 (16.3)
Cumulative methadone dose during outpatient weanb (mg) 30 (3.1–160) 33.3 (25.4)
Frequency (n) Percent (%)
Need for adjunctive medications 2 2
Prominent inpatient gastrointestinal symptoms 8 7
Prominent inpatient central nervous system symptoms 60 51
Safety outcomes Frequency (n) Percent (%)
Inpatient adverse events
Unsafe sleep practices 8 7
Newborn oversedation 5 4
Near suffocation 2 2
Fall or drop 1 1
Outpatient adverse eventsc
Alteration of planned wean after discharge 23 20
Suspected mishandling of medication by caregiver 10 9
Lacked medication to complete wean, no mishandling suspected 8 7
CPS involvement (not mutually exclusive) Frequency (n) Percent (%)
No involvement 60 51
Case opened antenatally or during hospitalization 30 26
Case opened after hospital dischargec 26 22
Placement with foster family after dischargec 24 21
Emergency services usec Frequency (n) Percent (%)
ED visit or readmission with 30 d of discharge 16 14
Possibly NAS-related 8 7
Not NAS-related 8 7
Abbreviations: CPS, child protective services; ED, emergency department; NAS, neonatal abstinence syndrome; SD, standard deviation.
aData on duration of outpatient wean available for 102 patients.
bData on cumulative dose available for 89 patients.
cData on outpatient events available for 115 patients.
American Journal of Perinatology
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and a majority did not require high-calorie feedings. Short
length of stay was attributed to early symptom stabilization
and related low rates of NAS complications.
One common argument against early methadone treat-
ment is a theoretical risk that longer durations of opioid
exposure may cause harm to the immature brain.25–31 New-
borns of mothers taking chronic opioids, however, have been
exposed to signiﬁcant opioid levels for the entire duration of
fetal life. No studies have examined the long-term impact of
the experience of severe withdrawal on the neonatal brain or
human development.45 Several studies of methadone effects
on the fetal brain report developmental concerns26–31 but do
not examine whether deﬁcits were related to medication
exposure, damage induced by the process of withdrawal, or a
combination. Although the ethical beneﬁts of extending
opioid exposure to provide a gentle withdrawal process
have been discussed in the literature,21,32,33 the medical risks
and beneﬁts have not been examined.
Research on NAS has documented the related and increasing
costs of treating affected newborns.2,4,42With substantial fund-
ing providedbystateMedicaid, the cost of treatment is a concern
for a wide range of public and private stakeholders. The mean
total charges per birth for the cohort who completed the early
treatment model were $10,946.96. These charges are signiﬁ-
cantly lower than the average U.S. 2012 charges reported to be
$66,700 per NAS case and $93,400 per inpatient pharmacologi-
cally treated NAS case.2 Mean reimbursement per case in our
cohort was 48% of charges and resulted in an average net loss of
$647.82. Comparison of charge and length of stay datawith that
reported nationally can be misleading, because several new-
borns with NAS might not qualify for an early treatment model
ormay require intensive care for reasons other thanwithdrawal.
However, if data on the exposure source reported by Tennessee’s
Department of Health is generally representative of national
trends, more than half of all NAS cases may be associated with
supervised opioid replacement therapies.13While our study did
not include amatched cohort for comparison, further analysis of
state data to identify a comparison group with the same exclu-
sion criteria is being performed and will be reported in a future
publication. Our study demonstrates that pharmacologic treat-
mentcanbeprovided ina combined inpatient/outpatient setting
that results in reduced lengthof stay,maternal-infant separation,
and cost, without sacriﬁcing safety or readmission rates.
Strengths of the current study included a consistent and
stable provider team over the course of model utilization,
development of a database for tracking adverse events and
related medical outcomes, and having an outpatient medical
home willing to provide standardized care for all discharged
patients. Potential limitations of this study included lack of a
control group, low numbers of neonates qualifying for the
early treatment protocol, adjustments made to the treatment
protocol over time, and an inability to deﬁne total opioid
exposure levels for the cohort. Of these, the most important
limitation was the fact that minor adjustments were made to
the treatment protocol over time. For example, standardized
weaning of 30 days or less was not implemented until 2012.
Prior to 2012, the pharmacists were not directed to limit the
length of the outpatient wean. As a result, the average
duration of treatment for the cohort was longer than the
duration for infants being treatedwith themodel today. There
were several cases of suspected medication mishandling
during the early years of our treatment protocol, all of which
occurredwhen newbornswere sent homewithmedication in
amultidose bottle. Such events did not occur after the change
to dispensing preﬁlled oral syringes. Although protocol
changes had the potential to impact results, the changes
were each designed to improve the quality of care and address
protocol weaknesses that were observed over time. A barrier
to replication of our treatment model may be a variation in
state laws related to allowable methadone prescribing.
Future research may include a prospective study with a
comparison group to determine the effectiveness of this inter-
vention in other regional hospitals with low-acuity nurseries. If
similar results are demonstrated, the model may be a safe and
effective tool for improving clinical outcomes for newborns
diagnosed with NAS. In addition, maintaining a database of
newborns with mild to moderate NAS who were treated with
early methadone may allow for future reporting of associated
long-term medical, developmental, and family outcomes.
Conclusion
This study is the ﬁrst to describe an approach to preventing
severe newborn opioid withdrawal using an early treatment
model. New models of care for NAS are needed; approaches
shown to be safe, effective, ethical, and economical have
widespread applicability. Establishing a viable model of
care for NAS treatment in low-acuity nurseries will provide
economic and social beneﬁts to this unique population of
patients in our community, state, and nation. Demonstrating
a reduction in health care costs using our model could impact
health policy and professional guidelines yet to be developed.
Further, our model is family- and patient-centered, promot-
ing education, engagement, and empowerment of families
during the course of treatment. It is hoped that in the long
term, the model will impact overall family success.
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